Matthew W Foehr - Net Worth and Insider Trading
Matthew W Foehr Net Worth
The estimated net worth of Matthew W Foehr is at least $42 Million dollars as of 2024-11-05. Matthew W Foehr is the President and COO of Ligand Pharmaceuticals Inc and owns about 173,354 shares of Ligand Pharmaceuticals Inc (LGND) stock worth over $19 Million. Matthew W Foehr is the President and CEO of OmniAb Inc and owns about 3,536,665 shares of OmniAb Inc (OABI) stock worth over $16 Million. Matthew W Foehr is also the Director of Viking Therapeutics Inc and owns about 111,250 shares of Viking Therapeutics Inc (VKTX) stock worth over $7 Million. Besides these, Matthew W Foehr also holds Ritter Pharmaceuticals Inc (RTTR) , China Teletech Holding Inc (CNCT) . Details can be seen in Matthew W Foehr's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Matthew W Foehr has not made any transactions after 2024-05-24 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Matthew W Foehr
Matthew W Foehr Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Matthew W Foehr owns 6 companies in total, including Ligand Pharmaceuticals Inc (LGND) , Viking Therapeutics Inc (VKTX) , and Ritter Pharmaceuticals Inc (RTTR) among others .
Click here to see the complete history of Matthew W Foehr’s form 4 insider trades.
Insider Ownership Summary of Matthew W Foehr
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Inc | 2022-05-13 | EVP and COO |
| VKTX | Viking Therapeutics Inc | 2022-05-02 | director |
| RTTR | Ritter Pharmaceuticals Inc | 2020-01-21 | director |
 | | 2015-06-24 | director |
| | 2022-11-01 | director & President & CEO |
| | 2024-05-24 | director & President & CEO |
Matthew W Foehr Latest Holdings Summary
Matthew W Foehr currently owns a total of 5 stocks. Among these stocks, Matthew W Foehr owns 173,354 shares of Ligand Pharmaceuticals Inc (LGND) as of May 13, 2022, with a value of $19 Million and a weighting of 45.85%. Matthew W Foehr owns 3,536,665 shares of OmniAb Inc (OABI) as of May 24, 2024, with a value of $16 Million and a weighting of 37.32%. Matthew W Foehr also owns 111,250 shares of Viking Therapeutics Inc (VKTX) as of May 2, 2022, with a value of $7 Million and a weighting of 16.82%. The other 2 stocks Ritter Pharmaceuticals Inc (RTTR) , China Teletech Holding Inc (CNCT) have a combined weighting of 0% among all his current holdings.
Latest Holdings of Matthew W Foehr
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| LGND | Ligand Pharmaceuticals Inc | 2022-05-13 | 173,354 | 111.28 | 19,290,833 |
| OABI | OmniAb Inc | 2024-05-24 | 3,536,665 | 4.44 | 15,702,793 |
| VKTX | Viking Therapeutics Inc | 2022-05-02 | 111,250 | 63.61 | 7,076,613 |
| RTTR | Ritter Pharmaceuticals Inc | 2018-08-17 | 2,190 | 0.45 | 986 |
| CNCT | China Teletech Holding Inc | 2003-05-14 | 14 | 0.00 | 0 |
Holding Weightings of Matthew W Foehr
Matthew W Foehr Form 4 Trading Tracker
According to the SEC Form 4 filings, Matthew W Foehr has made a total of 7 transactions in Ligand Pharmaceuticals Inc (LGND) over the past 5 years, including 1 buys and 6 sells. The most-recent trade in Ligand Pharmaceuticals Inc is the acquisition of 2,500 shares on May 13, 2022, which cost Matthew W Foehr around $206,900.
According to the SEC Form 4 filings, Matthew W Foehr has made a total of 10 transactions in OmniAb Inc (OABI) over the past 5 years, including 10 buys and 0 sells. The most-recent trade in OmniAb Inc is the acquisition of 240,000 shares on May 24, 2024, which cost Matthew W Foehr around $1 Million.
According to the SEC Form 4 filings, Matthew W Foehr has made a total of 3 transactions in Viking Therapeutics Inc (VKTX) over the past 5 years, including 2 buys and 1 sells. The most-recent trade in Viking Therapeutics Inc is the acquisition of 45,000 shares on May 2, 2022, which cost Matthew W Foehr around $111,150.
More details on Matthew W Foehr's insider transactions can be found in the Insider Trading History of Matthew W Foehr table.Insider Trading History of Matthew W Foehr
- 1
Matthew W Foehr Trading Performance
GuruFocus tracks the stock performance after each of Matthew W Foehr's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Matthew W Foehr is 2.69%. GuruFocus also compares Matthew W Foehr's trading performance to market benchmark return within the same time period. The performance of stocks bought by Matthew W Foehr within 3 months outperforms 13 times out of 26 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Matthew W Foehr's insider trading performs compared to the benchmark.
Performance of Matthew W Foehr
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 1.19 | | | | | |
| Relative Return to S&P 500(%) | 0.25 | | | | | |
Matthew W Foehr Ownership Network
Ownership Network List of Matthew W Foehr
Ownership Network Relation of Matthew W Foehr
Matthew W Foehr Owned Company Details
What does Ligand Pharmaceuticals Inc do?
Who are the key executives at Ligand Pharmaceuticals Inc?
Matthew W Foehr is the EVP and COO of Ligand Pharmaceuticals Inc. Other key executives at Ligand Pharmaceuticals Inc include CHIEF LEGAL OFFICER & Andrew Reardon , VP & Finance and CFO Matthew E Korenberg , and Chief Financial Officer Octavio Espinoza .
Ligand Pharmaceuticals Inc (LGND) Insider Trades Summary
Over the past 18 months, Matthew W Foehr made no insider transaction in Ligand Pharmaceuticals Inc (LGND). Other recent insider transactions involving Ligand Pharmaceuticals Inc (LGND) include a net sale of 70,748 shares made by Matthew E Korenberg , a net sale of 14,708 shares made by Octavio Espinoza , and a net sale of 13,500 shares made by Andrew Reardon .
In summary, during the past 3 months, insiders sold 57,925 shares of Ligand Pharmaceuticals Inc (LGND) in total and bought 2,500 shares, with a net sale of 55,425 shares. During the past 18 months, 119,043 shares of Ligand Pharmaceuticals Inc (LGND) were sold and 6,500 shares were bought by its insiders, resulting in a net sale of 112,543 shares.
Ligand Pharmaceuticals Inc (LGND)'s detailed insider trading history can be found in Insider Trading Tracker table.
Ligand Pharmaceuticals Inc Insider Transactions
Matthew W Foehr Mailing Address
Above is the net worth, insider trading, and ownership report for Matthew W Foehr. You might contact Matthew W Foehr via mailing address: 11119 North Torrey Pines Rd #200, La Jolla Ca 92037.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
